AzTrials
AzTrials

Colorectal Cancer (Locally Advanced or Metastatic)Phase 1/2NCT07693751

A Study to Assess Safety and Efficacy of SOT109 in Patients With Advanced Unresectable or Metastatic Colorectal Cancer

A Phase 1/2 study testing SOT109 in people with Colorectal Cancer (Locally Advanced or Metastatic), run by SOTIO Biotech a.s. at 3 sites in 2 countries.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

SOT109 is a special cancer medicine designed to find and kill certain cancer cells that carry a marker called CDH17, while causing less harm to healthy cells. The study consists of two parts, Part A and Part B. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
SOT109
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
100 participants
Where
3 sitesin 2 countries
Study dates
12 Aug 2026to 4 Jul 2028
Phase
Phase 1/2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • ≥18 years of age on the day of signing the ICF
  • Able to understand, sign, and provide written informed consent to participate in the trial
  • Performance status: Eastern Cooperative Oncology Group (ECOG) performance score 0-1. Patients with ECOG performance score 2 will be discussed with the sponsor's medical monitor to be agreed for inclusion
  • Estimated life expectancy ≥3 months as assessed by the investigator
  • An appropriate candidate for experimental therapy as assessed by the investigator
  • Agrees not to participate in other interventional clinical trial while enrolled in the present trial (with the exception of survival follow-up period)
Show all 41Show fewer
  • Absolute neutrophil count ≥1.5×109/L, platelets ≥100×109/L, hemoglobin ≥9 g/dL
  • Creatinine clearance ≥60 mL/min calculated by Cockcroft-Gault formula
  • Bilirubin ≤1.5× upper limits of normal (ULN), ALT and AST ≤2.5×ULN; in case of liver involvement: AST and ALT ≤5×ULN
  • Participants with a documented history of Gilbert syndrome may be eligible if:
  • Total bilirubin is ≤2.0 × ULN,
  • Direct (conjugated) bilirubin is within normal limits (≤ULN), and
  • There is no evidence of active liver disease, clinically significant hepatic impairment, hemolysis, or biliary obstruction, as determined by the investigator
  • Prothrombin time/international normalized ratio ≤1.5×ULN
  • Albumin ≥3.0 mg/dL
  • Serum concentrations of potassium, magnesium, and calcium with abnormalities of maximum grade 1 that should be treated according to standard practice
  • Left ventricular ejection fraction (LVEF) ≥50% as determined by echocardiography or nuclear medicine methodology (MUGA)
  • QTcF interval ≤470 msec on screening ECG
  • Histological or cytological evidence of advanced unresectable or metastatic colorectal cancer
  • Participants that received and progressed on standard systemic therapies (fluoropyrimidines, oxaliplatin, irinotecan, bevacizumab, and, only when locally indicated and available, a BRAF/RAS/HER2 inhibitor) and who have no further standard treatment options. Participants with a known microsatellite instability-high (MSI-H) status must have received treatment with an immune checkpoint inhibitor (if locally indicated and available) unless contraindicated
  • Measurable or non-measurable disease according to RECIST 1.1
  • Previous cancer therapies:
  • 18.1. Europe: previous cancer therapies and any agents that have not received regulatory approval for any indication must have been discontinued either ≥21 days prior to day 1 of cycle 1 or ≥5x half-life, whichever is longer; toxicities of earlier anticancer therapy must be grade ≤1 at the time of screening and prior to cycle 1 day 1 (exception: alopecia) 18.2. US: eligibility should be determined based on patient recovery from clinically significant adverse events from their most recent therapy or intervention prior to study enrollment
  • A female participant is eligible to participate if she is not pregnant, not breastfeeding, and one of the following conditions applies: 19.1. Not a woman of childbearing potential (WOCBP). A WOCBP is defined as fertile, following menarche, and until becoming postmenopausal unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy, and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy. However, in the absence of 12 months of amenorrhea, a single follicle stimulating hormone measurement is insufficient.
  • 19.2. A WOCBP who agrees to use a highly effective contraceptive method during the treatment period and for at least 6 months after the last dose of SOT109
  • WOCBP can only be included after a negative serum pregnancy test at screening
  • Highly effective contraception includes:
  • Combined (estrogen- and progestogen-containing) hormonal contraception associated with inhibition of ovulation:
  • Oral
  • Intravaginal
  • Transdermal
  • Progestogen-only hormonal contraception associated with inhibition of ovulation:
  • Oral
  • Injectable
  • Implantable
  • Intrauterine device
  • Intrauterine hormone-releasing system
  • Bilateral tubal occlusion
  • Vasectomized partner provided the partner is the sole sexual partner of the WOCBP participant and that the vasectomized partner has received medical assessment of the surgical success
  • Sexual abstinence defined as refraining from heterosexual intercourse during the entire treatment period and for at least 6 months after the last dose of SOT109. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the participant.
  • Male participants must agree to use a condom during the treatment period and for at least 6 months after the last dose of SOT109. Male participants wishing to become a father during or after the trial should consider sperm preservation. WOCBP partners of male participants should use highly effective contraception methods for 6 months after SOT109 discontinuation.

Who cannot join

  • Received radiation therapy ≤14 days before day 1 of cycle 1 or not recovered to grade ≤1 from treatment-related side effects
  • Any prior systemic therapy for metastatic cancer other than colorectal cancer; exception:
  • stable disease under hormonal treatment for prostate cancer, stable disease under hormonal treatment for breast cancer; radiochemotherapy is allowed if such treatment is completed at least 4 weeks prior to day 1 of cycle 1; participants must have recovered to grade ≤1 from all side effects (exception: alopecia)
  • Participants must not receive any concurrent antitumor therapy while participating in the trial. In exceptional circumstances where urgent palliative radiotherapy to symptomatic non-target lesions is clinically indicated, the case must be reviewed with the Principal Investigator (PI) and the intervention must receive prior approval from the sponsor
  • Vaccination with a live or live-attenuated vaccine within 30 days prior to the first dose of trial interventions; the full series (e.g., both doses of a two dose vaccination series) should be completed prior to dosing if feasible
  • Time since last transfusion of red blood cells ≤14 days before day 1 of cycle 1
Show all 20Show fewer
  • Severe preexisting medical conditions as per judgment of the investigator
  • History of interstitial pneumonitis or pulmonary fibrosis
  • Symptomatic central nervous system malignancy. Participants with asymptomatic or treated central nervous system metastases may be eligible if they are not treated with corticosteroids or anticonvulsants and the disease is stable for at least 60 days
  • Peripheral sensory neuropathy grade ≥2
  • Active infection requiring systemic therapy that is not clinically controlled before the signature of the ICF
  • Known symptomatic HIV positive, symptomatic active HBV, or symptomatic active HCV
  • Note:
  • Participants with HIV will be eligible if:
  • CD4+ T-cell counts ≥350 cells/μL
  • They have no history of AIDS-defining opportunistic infections
  • They are not currently on HIV therapy
  • Participants with HBV will be eligible if there is serologic evidence of a resolved prior HBV infection (HBsAg-negative and HBcAb-positive)
  • Participants with HCV will be eligible if they have completed curative antiviral treatment and have HCV viral load below the limit of quantification 12. Alcohol or drug abuse as determined by the investigator 13. Psychiatric condition or social situation that, in the opinion of the investigator, preclude that the participant is able to comply with trial requirements 14. New York Heart Association class ≥2 heart failure, unstable angina, coronary angioplasty, coronary stenting, coronary artery bypass graft, myocardial infarction, cerebrovascular accident or hypertensive crisis within 6 months prior to day 1 of cycle 1 15. History of major ventricular arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, Torsades de Pointes) 16. History or family history of congenital long QT syndrome 17. Bradycardia (<50 beats per minute) 18. Family history of sudden cardiac death before age 50 19. Major surgical intervention ≤28 days prior to ICF signature or incomplete wound healing after surgical intervention 20. Hypersensitivity or intolerance to any component of trial intervention 21. Medical history of inflammatory bowel disease or active inflammatory bowel disease (IBD)
  • Participants with signs or symptoms suggestive of IBD who have not undergone colonoscopy to rule out IBD will be excluded

Trial locations and contacts

3 sites in 2 countries. Contact the study team or a site near you to ask about taking part.

Richard Kapsa contact

(+420) 2241 74448

kapsa@sotio.com

3 sites in 2 countries

United States2 sites, 2 recruiting

  • NEXT Virginia

    Faifax, Virginia, 22031

    NEXT Virginia, 703 783 4510

    Recruiting

  • NEXT Houston

    Houston, Texas, 77054

    NEXT Houston, 210 580-9500

    Recruiting

Other trials in United States

Moldova1 site, 1 recruiting

  • Arensia Exploratory Medicine Research Unit, Institute of Oncology

    Chisinau

    Arensia Exploratory Medicine Research Unit, Institute of Oncol, +373 68541058

    Recruiting

Other trials in Moldova

About this study

Official title: A First-in-human Phase 1/2 Trial to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of SOT109 in Patients With Advanced Unresectable or Metastatic Colorectal Cancer

SOT109 is a special cancer medicine designed to find and kill certain cancer cells that carry a marker called CDH17, while causing less harm to healthy cells. The study consists of two parts, Part A and Part B. The goal of Part A is to collect information about SOT109, understand its effects, and see whether it is safe and well tolerated at different dose levels. Part B of the study collects information on which of the two selected safe dose levels chosen in Part A gives the best balance between benefit and risk.

Read the detailed description

The trial will consist of the following parts:

  • Part A: a multinational, multicenter, open-label, TITE-BOIN-guided trial to determine the MTD and RP2Ds, to evaluate the safety, PK, and preliminary efficacy of escalating doses of SOT109 in participants with advanced unresectable or metastatic colorectal cancer who have received and/or have been determined to be intolerant of all standard of care therapy known to confer clinical benefit.
  • Part B: This is a randomized, multinational, multicenter, open-label dose optimization trial evaluating the two recommended doses for optimization (RDOs) identified in Part A. After the determination of the MTD in Part A and identification of RDOs, a randomized dose optimization part will be initiated to evaluate the two selected RDOs and to identify the optimal biological dose that offers the best balance between benefit and risk and to evaluate safety and efficacy of SOT109 in participants with advanced unresectable or metastatic colorectal cancer who have no further standard treatment options.
Being tested
SOT109
Keywords
Colorectal Cancer
Medical subject headings
Colorectal Neoplasms, Neoplasm Metastasis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • SOT109Biological

    SOT109 is a CDH17-directed monoclonal antibody conjugated to a linker-payload, exatecan

Study groups in NCT07693751
Study groupRoleWhat they receive
SOT109 (Part A) dose level 1ExperimentalPatients with advanced unresectable or metastatic colorectal cancer treated with SOT109 given once every 21 days via the IV route over 30 (±15) minutes.
Receives: Biological: SOT109
SOT109 (Part A) dose level 2ExperimentalPatients with advanced unresectable or metastatic colorectal cancer treated with SOT109 given once every 21 days via the IV route over 30 (±15) minutes.
Receives: Biological: SOT109
SOT109 (Part A) dose level 3ExperimentalPatients with advanced unresectable or metastatic colorectal cancer treated with SOT109 given once every 21 days via the IV route over 30 (±15) minutes.
Receives: Biological: SOT109
SOT109 (Part A) dose level 4ExperimentalPatients with advanced unresectable or metastatic colorectal cancer treated with SOT109 given once every 21 days via the IV route over 30 (±15) minutes.
Receives: Biological: SOT109
SOT109 (Part A) dose level 5ExperimentalPatients with advanced unresectable or metastatic colorectal cancer treated with SOT109 given once every 21 days via the IV route over 30 (±15) minutes.
Receives: Biological: SOT109
SOT109 (Part B) recommended dose for optimization 1ExperimentalPatients with advanced unresectable or metastatic colorectal cancer treated with SOT109 given once every 21 days via the IV route over 30 (±15) minutes.
Receives: Biological: SOT109
SOT109 (Part B) recommended dose for optimization 2ExperimentalPatients with advanced unresectable or metastatic colorectal cancer treated with SOT109 given once every 21 days via the IV route over 30 (±15) minutes.
Receives: Biological: SOT109

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Part A: Maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of SOT109

    MTD will be selected as guided by the time to-event Bayesian optimal interval (TITEBOIN) design. The RP2D will be selected based on integrated evaluation of the totality of clinical and preclinical data, for all dose levels tested.

    Measured: At the end of Cycle 1 (one cycle is 21 days)

  2. Part B: Optimal dose of SOT109 for subsequent clinical trials

    Assessment of the safety and tolerability of two recommended doses under evaluation for dose optimization (RDOs) of SOT109 by evaluation of the occurrence of SOT109 related TEAEs, serious TEAEs, TEAEs leading to premature discontinuation of SOT109, deaths, and clinical laboratory test abnormalities of grade 3 or higher according to NCI CTCAE Version 6.0

    Measured: Cycle 1 Day 1 up to 30 days after the last dose (each cycle is 21 days)

  3. Part B: Objective Response Rate (ORR) of SOT109

    Percentage of participants who achieve a Best Overall Response of Complete Response (CR) or Partial Response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

    Measured: From Day 1 of Cycle 1 (one cycle is 21 days) until disease progression, initiation of new anticancer therapy, withdrawal of consent, or study discontinuation, whichever comes first, to be assessed up to approximately 9 months

  4. Part B: Duration of Response (DoR) of SOT109

    The time from the first documentation of objective response (CR or PR) to the first documented date of progressive disease (PD) according to RECIST v1.1.

    Measured: From the date of first documented objective response until disease progression, initiation of new anticancer therapy, withdrawal of consent, or study discontinuation, whichever comes first, assessed up to approximately 9 months.

Secondary outcomes (11)

  1. Part A: Safety and Tolerability of SOT109

    The occurrence of dose-limiting toxicities (DLTs), SOT109-related treatment-emergent adverse events (TEAEs), serious TEAEs, TEAEs leading to premature discontinuation of SOT109, deaths, and clinical laboratory test abnormalities of grade 3 or higher according to National Cancer Institute (NCI) common terminology criteria for adverse events (CTCAE) Version 6.0

    Measured: From Cycle 1 Day 1 (one cycle is 21 days) assessed for approximately 12 months

  2. Part A: Characterization of maximum concentration (Cmax)

    Cmax in plasma of total antibody, conjugated antibody and free exatecan.

    Measured: From Cycle 1 Day 1 up to approximately 12 months (each cycle is 21 days)

  3. Part A: Characterization of time to maximum concentration (Tmax)

    Time to maximum concentration of total antibody, conjugated antibody and free exatecan.

    Measured: From Cycle 1 Day 1 up to approximately 12 months (each cycle is 21 days)

  4. Part A: Characterization of area under the curve

    Area under the concentration versus time curve calculated for total antibody, conjugated antibody and free exatecan.

    Measured: From Cycle 1 Day 1 up to approximately 12 months (each cycle is 21 days)

  5. Part A: Preliminary anticancer activity of SOT109

    Tumor response per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by CDH17 expression

    Measured: From Day 1 of Cycle 1 (one cycle is 21 days) until disease progression, initiation of new anticancer therapy, withdrawal of consent, or study discontinuation, whichever comes first, to be assessed up to approximately 12 months

  6. Part A: Immunogenicity of SOT109 as Evaluated by Anti-Drug Antibody (ADA) Incidence

    Proportion of participants who test positive for ADAs to SOT109.

    Measured: From Cycle 1 Day 1 up to approximately 12 months (each cycle is 21 days)

  7. Part B: Progression-Free Survival (PFS) of SOT109

    Progression-free survival is defined as the time from Cycle 1 Day 1 to the first documented date of progressive disease (PD) according to RECIST v1.1, or death from any cause, whichever occurs first

    Measured: From Cycle 1 Day 1 (one cycle is 21 days) until first documented disease progression or death from any cause, assessed up to approximately 9 months

  8. Part B: Characterization of Cmax

    Evaluation of the maximum plasma concentration (Cmax) for total antibody, conjugated antibody, and free exatecan payload.

    Measured: From Cycle 1 Day 1 up to approximately 9 months (each cycle is 21 days)

  9. Part B: Characterization of Tmax

    Evaluation of the time to maximum plasma concentration (Tmax) for total antibody, conjugated antibody, and free payload.

    Measured: From Cycle 1 Day 1 up to approximately 9 months (each cycle is 21 days)

  10. Part B: Characterization of area under the curve

    To characterize the total drug exposure over time (AUC) for total antibody, conjugated antibody, and free payload.

    Measured: From Cycle 1 Day 1 up to approximately 9 months (each cycle is 21 days)

  11. Part B: Immunogenicity of SOT109 as Evaluated by Anti-Drug Antibody (ADA) Incidence

    Proportion of participants who test positive for ADAs to SOT109. The potential impact of ADA status on the pharmacokinetic (PK) profiles (Cmax, AUC, Tmax) of SOT109 will be evaluated by comparing PK data between ADA-positive and ADA-negative participants

    Measured: From Cycle 1 Day 1 up to approximately 9 months (each cycle is 21 days)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Jul 2026
  2. Study start12 Aug 2026
  3. Primary completion29 Nov 2027 (estimated)
  4. Study completion4 Jul 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1/2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Sequential
Model description
Part A: 5 cohorts, dose-escalation, Time-to-Event Bayesian Optimal Interval Design (TITE-BOIN) trial. Part B: Randomized, open-label dose optimization trial
Masking
None (open label)
Enrolment
100 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07693751
Sponsor's protocol ID
109S01
Other IDs
2026-526235-19-00, CADENCIA-01
Status last verified
Sep 2026
First submitted
25 Jun 2026
Last updated
21 Sep 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 1/2 study testing SOT109 in people with Colorectal Cancer (Locally Advanced or Metastatic), run by SOTIO Biotech a.s. at 3 sites in 2 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 41 inclusion and 20 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 21 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in United States, Moldova. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Richard Kapsa ((+420) 2241 74448, kapsa@sotio.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Part A: Maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of SOT109 (time frame: At the end of Cycle 1 (one cycle is 21 days)). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07693751.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Sep 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in